CA3097622A1 - Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices - Google Patents

Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices Download PDF

Info

Publication number
CA3097622A1
CA3097622A1 CA3097622A CA3097622A CA3097622A1 CA 3097622 A1 CA3097622 A1 CA 3097622A1 CA 3097622 A CA3097622 A CA 3097622A CA 3097622 A CA3097622 A CA 3097622A CA 3097622 A1 CA3097622 A1 CA 3097622A1
Authority
CA
Canada
Prior art keywords
group
atom
alkyl group
alkyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3097622A
Other languages
English (en)
French (fr)
Inventor
Mouad Alami
Olivier Provot
Abdallah Hamze
Ilhem KHELIFI
Timothee Naret
Sebastien Apcher
Romain DARRIGRAND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Original Assignee
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut Gustave Roussy, Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay filed Critical Centre National de la Recherche Scientifique
Publication of CA3097622A1 publication Critical patent/CA3097622A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
CA3097622A 2018-04-27 2019-04-26 Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices Pending CA3097622A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1853709A FR3080620B1 (fr) 2018-04-27 2018-04-27 Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
FR1853709 2018-04-27
PCT/FR2019/050982 WO2019207257A1 (fr) 2018-04-27 2019-04-26 Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices

Publications (1)

Publication Number Publication Date
CA3097622A1 true CA3097622A1 (fr) 2019-10-31

Family

ID=63036097

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3097622A Pending CA3097622A1 (fr) 2018-04-27 2019-04-26 Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices

Country Status (9)

Country Link
US (2) US11634405B2 (enExample)
EP (1) EP3784662B1 (enExample)
JP (1) JP7408894B2 (enExample)
AU (1) AU2019259112B2 (enExample)
CA (1) CA3097622A1 (enExample)
DK (1) DK3784662T3 (enExample)
ES (1) ES2932370T3 (enExample)
FR (1) FR3080620B1 (enExample)
WO (1) WO2019207257A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111825610B (zh) * 2020-06-24 2023-03-31 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途
CN115417860B (zh) * 2020-08-03 2023-10-20 中国药科大学 一种具有抗肿瘤活性的喹唑啉类衍生物及其合成方法和用途
CN113173915B (zh) * 2021-03-29 2022-12-09 中南大学湘雅医院 抗皮肤肿瘤化合物及其应用
CN113620874B (zh) * 2021-08-10 2024-02-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基-喹啉衍生物及其用途
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111377A (pt) 2000-06-06 2003-06-03 Pfizer Prod Inc Derivados de tiofeno úteis como agentes anticancerìgenos
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
CA2545340A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
AP2006003619A0 (en) * 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
AU2006204052A1 (en) 2005-01-03 2006-07-13 Cytovia, Inc. Method of treating brain cancer
GB0508717D0 (en) 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
WO2007034143A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab Quinazoline derivatives as anticancer agents
FR2914640B1 (fr) 2007-04-04 2012-11-16 Centre Nat Rech Scient Iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de polymerisation de la tubuline

Also Published As

Publication number Publication date
US11634405B2 (en) 2023-04-25
US20230203005A1 (en) 2023-06-29
AU2019259112B2 (en) 2024-02-08
JP2021522244A (ja) 2021-08-30
WO2019207257A1 (fr) 2019-10-31
AU2019259112A1 (en) 2020-11-26
WO2019207257A8 (fr) 2019-11-21
EP3784662A1 (fr) 2021-03-03
ES2932370T3 (es) 2023-01-18
FR3080620A1 (fr) 2019-11-01
FR3080620B1 (fr) 2021-11-12
US12371417B2 (en) 2025-07-29
EP3784662B1 (fr) 2022-11-09
US20210230140A1 (en) 2021-07-29
DK3784662T3 (da) 2022-12-19
JP7408894B2 (ja) 2024-01-09

Similar Documents

Publication Publication Date Title
EP3784662B1 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
CA2769474C (fr) Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
WO2005016326A2 (en) Analogs of thalidomide as potential angiogenesis inhibitors
FR3066761A1 (fr) Nouveaux composes inhibiteurs des canaux ioniques
KR20130016041A (ko) 신규한 아닐린 유도체 및 이의 용도
TW202313559A (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
EP3400210B1 (fr) Composés"multi-cibles"à activité inhibitrice des histone-désacétylases et de la polymérisation de la tubuline pour son utilisation dans le traitement du cancer
CA2567020A1 (fr) Produits biaryl aromatiques, compositions les contenant et utilisation comme medicaments
JP2025527175A (ja) ウロリチン誘導体の治療的使用
JP2022538074A (ja) タンパク質分解のための化合物、組成物、および方法
CA2902276A1 (fr) Heterocycles phosphores analogues de sucres a activite antimetastatique
FR3019819A1 (fr) Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline
CN108473449B (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的砜脒及其制备方法和用途
EP3687512A1 (fr) Agents inhibant la proteine tctp pour le traitement de maladies proliferatives, de maladies infectieuses, d'allergies, d'inflammations et/ou de l'asthme
CN106496132A (zh) N‑(4‑取代苯基)‑2‑取代乙酰胺类化合物及其作为sirt2蛋白抑制剂的用途
JP2021517167A (ja) タンパク質分解を阻害するための化合物および癌の治療におけるその使用方法
CN120943801A (zh) 一种具有取代二苯醚结构的小分子化合物及其制备和应用
TW379220B (en) Pyrazolidine derivative, radical scavenger, brain--infarction depressant, and brain-edma depressant
CN120698929A (zh) 一种联苯烯烃类化合物及其药物组合物和应用
CN108186630A (zh) 靛红类似物在制备抗肿瘤药物中的应用
CA2859721A1 (fr) Derives piperazinyles pour le traitement de cancers
FR2955108A1 (fr) Utilisation de derives de pyrrolopyridine comme activateurs de nurr-1, pour le traitement de la maladie de parkinson

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231227

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250123

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250325

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250325

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250325

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250523

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250723

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250723

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260427

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260427

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260427

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260427